Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion's shares soared 92 percent to $2.56 in mid-afternoon trade on the Nasdaq today after the firm announced that a panel of the American Medical Association approved the company's application for a Category 1 CPT code for its OVA1 ovarian cancer test.

The new code assigned to OVA1 becomes effective Jan. 1, 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.